Supplementary Material1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

Katherine A. Janeway; Alexander J. Chou; Allen B. Buxton; Joel M. Reid; Michael S. Isakoff; Lisa M. Kopp; Pooja Hingorani; Jill L. Lee; John J. Doski; Heike Daldrup-Link; Laura Hall; Robert Lor Randall; Damon R. Reed; Steven G. DuBois; Mark Krailo; Holcombe E. Grier; Richard Greg Gorlick

doi:10.1158/1078-0432.31006834

Supplementary Material1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

2026 Open access

Read full text

Authors: Katherine A. Janeway, Alexander J. Chou, Allen B. Buxton, Joel M. Reid, Michael S. Isakoff, Lisa M. Kopp, Pooja Hingorani, Jill L. Lee, John J. Doski, Heike Daldrup-Link, Laura Hall, Robert Lor Randall

+5 more

Damon R. Reed, Steven G. DuBois, Mark Krailo, Holcombe E. Grier, Richard Greg Gorlick

DOI: 10.1158/1078-0432.31006834

Cited by: 0

Fields of Study & Subjects

Bone Metabolism and Diseases Bone Tumor Diagnosis and Treatments Bone health and treatments

Publication details

Publication date: 6 January 2026